{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:06Z","timestamp":1791006906503,"version":"4.1.0"},"reference-count":62,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/irdr.2026.01061","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:10:00Z","timestamp":1787004600000},"page":"200-218","source":"Crossref","is-referenced-by-count":0,"title":["Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework"],"prefix":"10.5582","volume":"15","author":[{"given":"Yue","family":"Han","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China."},{"name":"Division of Global Health &amp; Medicine, Bureau of Health Emergency and Management, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Ge","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Medical Technology, Clinical College of Anhui Medical University, Hefei, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Global Health &amp; Medicine, Bureau of Health Emergency and Management, Japan Institute for Health Security, Tokyo, Japan."},{"name":"National College of Nursing, Japan (NCNJ), Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Ministry of Health, Labour and Welfare, Japan. Designated intractable diseases: Diagnostic criteria, severity classifications, and clinical survey forms, Nos. 1-348 (April 2026). <i>https:\/\/www.mhlw.go.jp\/stf\/newpage_53881.html<\/i> (accessed August 3, 2026)."},{"key":"2","unstructured":"2. Ministry of Health, Labour and Welfare, Japan. Measures for intractable diseases under the Act on Medical Care for Patients with Intractable Diseases. <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/nanbyou\/index.html<\/i> (accessed August 3, 2026)."},{"key":"3","unstructured":"3. Nanbyo Information Center, Japan. Designated intractable diseases: Skin and connective tissue disorders. <i>https:\/\/www.nanbyou.or.jp\/entry\/5480<\/i> (accessed August 3, 2026). (in Japanese)."},{"key":"4","unstructured":"4. US Food and Drug Administration. Rare diseases at FDA. https:\/\/www.fda.gov\/patients\/rare-diseases-fda (accessed August 3, 2026)."},{"key":"5","unstructured":"5. European Medicines Agency. Orphan designation: Overview. <i>https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/orphan-designation-overview<\/i> (accessed August 3, 2026)."},{"key":"6","unstructured":"6. Ministry of Health, Labour and Welfare, Japan. Diagnostic criteria and severity classifications for designated intractable diseases: Official notification. <i>https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=00tc8021&amp;dataType=1<\/i> (accessed August 3, 2026). (in Japanese)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hirai Y, Kodama Y, Moriwaki S, Noda A, Cullings HM, MacPhee DG, Kodama K, Mabuchi K, Kraemer KH, Land CE, Nakamura N. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. Mutat Res. 2006; 601:171-178.","DOI":"10.1016\/j.mrfmmm.2006.06.010"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C. Xeroderma pigmentosum clinical practice guidelines. J Dermatol. 2017; 44:1087-1096.","DOI":"10.1111\/1346-8138.13907"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Munetsugu T, Fujimoto T, Oshima Y, Sano K, Murota H, Satoh T, Iwase S, Asahina M, Nakazato Y, Yokozeki H. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol. 2017; 44:394-400.","DOI":"10.1111\/1346-8138.13649"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Kageyama R, Sakamoto K, Nakamizo S, Kabashima K, Nakagawa M, Nagao K, Honda T. Cellular stress-induced eccrine gland dysfunction as a potential mechanism in acquired idiopathic generalized anhidrosis. J Invest Dermatol. 2026. Online ahead of print. doi:10.1016\/j.jid.2026.03.022.","DOI":"10.1016\/j.jid.2026.03.022"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Sato N, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018; 138:1201-1204.","DOI":"10.1016\/j.jid.2017.11.023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sugiyama S, Yamamoto T, Aoyama Y. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study. J Dermatol. 2022; 49:697-702.","DOI":"10.1111\/1346-8138.16394"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kuwata H, Nishioka Y, Noda T, Kubo S, Myojin T, Higashino T, Takahashi Y, Ishii H, Imamura T. Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database. J Diabetes Investig. 2022; 13:460-467.","DOI":"10.1111\/jdi.13676"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kanazawa N, Nakamura T, Mikita N, Furukawa F. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol. 2013; 40:749-751.","DOI":"10.1111\/1346-8138.12227"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sugiura K, Takemoto A, Yamaguchi M, <i>et al<\/i>. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013; 133:2514-2521.","DOI":"10.1038\/jid.2013.230"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakatani K, Ueta M, Khor SS, Hitomi Y, Okudaira Y, Masuya A, Wada Y, Sotozono C, Kinoshita S, Inoko H, Tokunaga K. Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. Sci Rep. 2019; 9:16240.","DOI":"10.1038\/s41598-019-52619-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Phillips EJ, Sukasem C, Whirl-Carrillo M, M\u00fcller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018; 103:574-581.","DOI":"10.1002\/cpt.1004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Muto A, Watanabe S, Waseda Y, <i>et al<\/i>. Anti-MDA5 antibody-positive interstitial lung disease without prominent skin or muscle manifestations: A high-risk and potentially overlooked subgroup. Respir Med. 2026; 252:108629.","DOI":"10.1016\/j.rmed.2025.108629"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hata K, Kotani T, Matsuda S, Fujiki Y, Suzuka T, Kiboshi T, Wada Y, Shiba H, Shoda T, Kagitani M, Takeuchi T. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease. Int J Rheum Dis. 2024; 27:e14999.","DOI":"10.1111\/1756-185X.14999"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Watanabe T, Taniguchi M, Ogura S, Asou M, Takayanagi S, Sokai Y, Tsuji Y, Mori KP, Endo T, Nakajima T, Imura Y, Tsukamoto T. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series. Ther Apher Dial. 2024; 28:432-441.","DOI":"10.1111\/1744-9987.14106"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Arima K, Kinoshita A, Mishima H, <i>et al<\/i>. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A. 2011; 108:14914-14919.","DOI":"10.1073\/pnas.1106015108"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ohmura K. Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes. J Inflamm Res. 2019; 12:259-265.","DOI":"10.2147\/JIR.S194098"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yamagami J, Kurihara Y, Funakoshi T, <i>et al<\/i>. Rituximab therapy for intractable pemphigus: A multicenter, open-label, single-arm, prospective study of 20 Japanese patients. J Dermatol. 2023; 50:175-182.","DOI":"10.1111\/1346-8138.16597"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yamagami J, Ujiie H, Aoyama Y, Ishii N, Tateishi C, Ishiko A, Ichijima T, Hagihara S, Hashimoto K, Amagai M. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton&apos;s tyrosine kinase inhibitor, in pemphigus. J Dermatol Sci. 2021; 103:135-142.","DOI":"10.1016\/j.jdermsci.2021.07.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, Avetisova E, Maloney J, Laws E, Mortensen E, Dubost-Brama A, Shabbir A. Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024; 41:2991-3002.","DOI":"10.1007\/s12325-024-02810-3"},{"key":"26","unstructured":"26. ClinicalTrials.gov. A study to evaluate the efficacy and safety of dupilumab in adult patients with bullous pemphigoid (LIBERTY-BP). NCT04206553. <i>https:\/\/clinicaltrials.gov\/study\/NCT04206553<\/i> (accessed August 3, 2026)."},{"key":"27","unstructured":"27. US Food and Drug Administration. Dupixent (dupilumab) prescribing information. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761055s070lbl.pdf<\/i> (accessed August 3, 2026)."},{"key":"28","unstructured":"28. Pharmaceuticals and Medical Devices Agency, Japan. Dupixent (dupilumab): Japanese prescribing information, revised March 2026. <i>https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_4490405G1024_1_19<\/i> (accessed August 3, 2026). (in Japanese)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, <i>et al<\/i>. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022; 387:2211-2219.","DOI":"10.1056\/NEJMoa2206663"},{"key":"30","unstructured":"30. Pharmaceuticals and Medical Devices Agency, Japan. Review report: Vyjuvek Gel (beremagene geperpavec). <i>https:\/\/www.pmda.go.jp\/regenerative_medicines\/2025\/R20250901001\/252524000_30700FZI00001_A100_1.pdf<\/i> (accessed August 3, 2026). (in Japanese)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Tang JY, Marinkovich MP, Wiss K, <i>et al<\/i>. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): A two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet. 2025; 406:163-173.","DOI":"10.1016\/S0140-6736(25)00778-0"},{"key":"32","unstructured":"32. US Food and Drug Administration. ZEVASKYN (prademagene zamikeracel): Product information and approval documents. <i>https:\/\/www.fda.gov\/vaccines-blood-biologics\/zevaskyn<\/i> (accessed August 3, 2026)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Mazereeuw-Hautier J, Paller AS, Dreyfus I, <i>et al<\/i>. Management of congenital ichthyoses: Guidelines of care: Part one: 2024 update. Br J Dermatol. 2025; 193:16-27.","DOI":"10.1093\/bjd\/ljaf076"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mazereeuw-Hautier J, Paller AS, O&apos;Toole E, <i>et al<\/i>. Management of congenital ichthyoses: Guidelines of care: Part two: 2024 update. Br J Dermatol. 2025; 193:28-43.","DOI":"10.1093\/bjd\/ljaf077"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Mazereeuw-Hautier J, Granier Tournier C, Hernandez-Martin A, <i>et al<\/i>. Biologics in congenital ichthyosis: Are they effective? Br J Dermatol. 2025; 192:327-334.","DOI":"10.1093\/bjd\/ljae420"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Porro AM, Seque CA, Miyamoto D, N\u00f3brega DVM, Enokihara MMSSE, Santi CG. Hailey-Hailey disease: Clinical, diagnostic and therapeutic update. An Bras Dermatol. 2024; 99:651-661.","DOI":"10.1016\/j.abd.2023.12.003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ly S, Beylot-Barry M, Seneschal J. Refractory anogenital Hailey-Hailey disease successfully treated with topical ruxolitinib. J Eur Acad Dermatol Venereol. 2025; 39:e786-e787.","DOI":"10.1111\/jdv.20620"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Marrakchi S, Guigue P, Renshaw BR, <i>et al<\/i>. Interleukin- 36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011; 365:620-628.","DOI":"10.1056\/NEJMoa1013068"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bachelez H, Choon SE, Marrakchi S, <i>et al<\/i>. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021; 385:2431-2440.","DOI":"10.1056\/NEJMoa2111563"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaci D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): An international, multicentre, randomised, placebo-controlled trial. Lancet. 2023; 402:1541-1551.","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Morita A, Tsai TF, Yap Wen Yee E, Okubo Y, Imafuku S, Zheng M, Li L, Quaresma M, Thoma C, Choon SE. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil 1 study. J Dermatol. 2023; 50:183-194.","DOI":"10.1111\/1346-8138.16609"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Morita A, Tada Y, Tsunemi Y, Komine M, Kanekura T, Imafuku S, Takahashi T, Ding X, Pillai N, Saitoh M, Simoes RS, P\u00f6ntynen N, Yamanaka K. Real-world safety profile of spesolimab in generalized pustular psoriasis: Insights from Japan as part of a multinational expanded access program (EAP). J Dermatol. 2026; 53:351-356.","DOI":"10.1111\/1346-8138.70122"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Miyamoto T, Izawa K, Masui S, <i>et al<\/i>. Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: Results of a nationwide survey. Arthritis Rheumatol. 2024; 76:949-962.","DOI":"10.1002\/art.42808"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kato C, Sasajima T, Nishikomori R. Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: Final results from a post-marketing surveillance in Japan. Mod Rheumatol. 2026; 36:447-455.","DOI":"10.1093\/mr\/roaf104"},{"key":"45","unstructured":"45. Japan Registry of Clinical Trials. A clinical study of baricitinib in patients with type I interferonopathies including Nakajo-Nishimura syndrome, CANDLE, SAVI, and Aicardi-Goutieres syndrome. jRCT2031200152. <i>https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCT2031200152<\/i> (accessed August 3, 2026)."},{"key":"46","unstructured":"46. Ministry of Health, Labour and Welfare, Japan. STING-associated vasculopathy with onset in infancy (designated intractable disease No. 345): Diagnostic criteria and severity classification. Effective April 2025. <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000084783.html<\/i> (accessed August 3, 2026). (in Japanese)."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Sanchez GAM, Reinhardt A, Ramsey S, <i>et al<\/i>. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018; 128:3041-3052.","DOI":"10.1172\/JCI98814"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Kretzschmar G, Pi\u00f1ero P\u00e1ez L, Tan Z, <i>et al<\/i>. Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (anifrolumab) in patients with type I interferonopathies. J Clin Immunol. 2025; 45:31.","DOI":"10.1007\/s10875-024-01826-2"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008; 14:1343-1350.","DOI":"10.1038\/nm.1884"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Sagun JP, Khan SG, Imoto K, Tamura D, Oh KS, DiGiovanna JJ, Kraemer KH. Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients. PLoS Genet. 2024; 20:e1011265.","DOI":"10.1371\/journal.pgen.1011265"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Suenobu S, Terashima K, Akiyama M, Oguri T, Watanabe A, Sugeno M, Higashimori M, So K, Nishida Y. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study. Neurooncol Adv. 2023; 5:vdad054.","DOI":"10.1093\/noajnl\/vdad054"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Gross AM, Reid OH, Baldwin LA, Cannon A, Choo-Wosoba H, Steinberg SM, Lobbous M, Wolters PL, Pichard DC, Tibery CM, Dombi E, Derdak J, Widemann BC, Korf BR. Treatment of cutaneous neurofibromas in neurofibromatosis type 1 with MEK inhibitor selumetinib: A nonrandomized clinical trial. JAMA Dermatol. 2025; 161:533-537.","DOI":"10.1001\/jamadermatol.2024.6574"},{"key":"53","unstructured":"53. ClinicalTrials.gov. Topical NFX-179 gel f o r cutaneous neurofibromas in neurofibromatosis type 1. NCT04435665. <i>https:\/\/clinicaltrials.gov\/study\/NCT04435665<\/i> (accessed August 3, 2026)."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Hamada I, Yukutake Y, Morita Y, Ishikawa N, Shimizu K, Wataya-Kaneda M. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex. J Dermatol. 2024; 51:752-758.","DOI":"10.1111\/1346-8138.17220"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Martin L, Spiering W, Aelbrecht K, <i>et al<\/i>. REACT-PXE: A consensus on diagnosis and future research concerning pseudoxanthoma elasticum (PXE). Ann Dermatol Venereol. 2026; 153:103440.","DOI":"10.1016\/j.annder.2025.103440"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kranenburg G, de Jong PA, Bartstra JW, <i>et al<\/i>. Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum. J Am Coll Cardiol. 2018; 71:1117-1126.","DOI":"10.1016\/j.jacc.2017.12.062"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Clotaire L, Rubera I, Duranton C, Gal J, Chamorey E, Humeau H, Yamani S, Chiaverini C, Willoteaux S, Padovani B, Mourozeau L, Mainguy A, Baillif S, Martin L, Leftheriotis G. The PROPHECI trial: A phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate. Trials. 2025; 26:30.","DOI":"10.1186\/s13063-024-08666-w"},{"key":"58","unstructured":"58. ClinicalTrials.gov. INZ-701 in adults with ABCC6 deficiency\/pseudoxanthoma elasticum. NCT05030831. <i>https:\/\/clinicaltrials.gov\/study\/NCT05030831<\/i> (accessed August 3, 2026)."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Murcia Casas B, Carrillo Linares JL, Baquero Aranda I, Rioja Villodres J, Merino Boh\u00f3rquez V, Gonz\u00e1lez Jim\u00e9nez A, Rico Corral M\u00c1, Bosch R, S\u00e1nchez Chaparro M\u00c1, Garc\u00eda Fern\u00e1ndez M, Valdivielso P. Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: A double-blind, randomized, placebo-controlled crossover trial. Int J Mol Sci. 2023; 24:4899.","DOI":"10.3390\/ijms24054899"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Testa LC, Obiri-Yeboah D, Said H, Qu P, Levine MA, Alameh MG, Musunuru K, Li Q, Wang X. Liver-directed base editing of ABCC6 prevents ectopic calcification in a variant-humanized mouse model of pseudoxanthoma elasticum. Mol Ther Nucleic Acids. 2025; 36:102769.","DOI":"10.1016\/j.omtn.2025.102769"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Meliko\u011flu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Trial of apremilast for oral ulcers in Beh\u00e7et&apos;s syndrome. N Engl J Med. 2019; 381:1918-1928.","DOI":"10.1056\/NEJMoa1816594"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Takeno M, Dobashi H, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Paris M, Chen M, Ishigatsubo Y. Apremilast in a Japanese subgroup with Behcet&apos;s syndrome: Results from a phase 3, randomised, double-blind, placebo-controlled study. Mod Rheumatol. 2022; 32:413-421.","DOI":"10.1093\/mr\/roab008"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01061\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:38Z","timestamp":1791005738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01061\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2026.01061","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01061"}}